The Outcome of HyperCVAD Combined with Alemtuzumab for the Treatment of Aggressive T-Cell and NK-Cell Neoplasms.
We report our experience in using six cycles of hyperCVAD in combination with alemtuzumab for the treatment of aggressive T-cell and NK/T-cell neoplasms. Seven females and six males with the median age of 41 (range 18–60) diagnosed with T-cell acute lymphoblastic lymphoma and peripheral T-cell...
Saved in:
Main Authors: | , , , , , , |
---|---|
Format: | E-Article |
Language: | English |
Published: |
Elsevier Ltd.
2011
|
Subjects: | |
Online Access: | http://ir.unimas.my/id/eprint/12281/7/A%20randomized%20double%20blind%20control%20trial%20comparing%20filgrastim%20%28abstract%29.pdf http://ir.unimas.my/id/eprint/12281/ http://dx.doi.org/10.1016/j.transci.2015.03.017 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Universiti Malaysia Sarawak |
Language: | English |